Edwards Lifesciences Corporation (EW)

$76.55

-1.01 (-1.30%)
Rating:
Recommendation:
Buy
Symbol EW
Price $76.55
Beta 1.044
Volume Avg. 4.45M
Market Cap 47.328B
Shares () -
52 Week Range 67.13-131.73
1y Target Est -
DCF Unlevered EW DCF ->
DCF Levered EW LDCF ->
ROE 24.47% Buy
ROA 16.89% Buy
Operating Margin -
Debt / Equity 38.93% Neutral
P/E 32.85 Strong Buy
P/B 7.63 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest EW news


Mr. Michael Mussallem
Healthcare
Medical Devices
New York Stock Exchange

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.